Pfizer has stopped the development of its weight loss pill after a patient experienced a liver injury that was potentially ...

Nestlé unveils science-backed protein drinks to help manage hunger, support muscle health and aid weight loss for GLP-1 users ...

Pfizer has halted the development of the experimental weight-loss pill danuglipron following a trial. A patient experienced a ...

Kilow will also provide access to treatments like GLP-1 medications like Ozempic, Wegovy ...

Explore the benefits of Mochi Health, a telehealth platform offering personalized weight loss solutions and support.

Closing the trading session at $12.92 yesterday, the stock hovers close to its 52-week low of $12.30 reached on April 7.MED Stock's Price PerformanceImage Source: Zacks Investment ResearchThis ...

Canaccord initiated coverage of Fractyl Health (GUTS) with a Buy rating and $12 price target Local administration to the pancreas combined ...

NEW YORK, NY, USA I April 14, 2025 I Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in people taking the potent weight loss drugs.

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Pfizer's pursuit of a daily pill to tackle obesity has hit a setback. The pharmaceuticals giant has paused development of its ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...